Literature DB >> 30316012

Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.

Aaron S Mansfield1, Tobias Peikert2, James B Smadbeck3, Julia B M Udell4, Enrique Garcia-Rivera5, Laura Elsbernd6, Courtney L Erskine6, Virginia P Van Keulen6, Farhad Kosari3, Stephen J Murphy3, Hongzheng Ren7, Vishnu V Serla3, Janet L Schaefer Klein3, Giannoula Karagouga3, Faye R Harris3, Carlos Sosa3, Sarah H Johnson3, Wendy Nevala6, Svetomir N Markovic1, Aaron O Bungum2, Eric S Edell2, Haidong Dong8, John C Cheville7, Marie Christine Aubry7, Jin Jen9, George Vasmatzis10.   

Abstract

INTRODUCTION: Malignant pleural mesothelioma is a disease primarily associated with exposure to the carcinogen asbestos. Whereas other carcinogen-related tumors are associated with a high tumor mutation burden, mesothelioma is not. We sought to resolve this discrepancy.
METHODS: We used mate-pair (n = 22), RNA (n = 28), and T cell receptor sequencing along with in silico predictions and immunologic assays to understand how structural variants of chromosomes affect the transcriptome.
RESULTS: We observed that inter- or intrachromosomal rearrangements were present in every specimen and were frequently in a pattern of chromoanagenesis such as chromoplexy or chromothripsis. Transcription of rearrangement-related junctions was predicted to result in many potential neoantigens, some of which were proven to bind patient-specific major histocompatibility complex molecules and to expand intratumoral T cell clones. T cells responsive to these predicted neoantigens were also present in a patient's circulating T cell repertoire. Analysis of genomic array data from the mesothelioma cohort in The Cancer Genome Atlas suggested that multiple chromothriptic-like events negatively impact survival.
CONCLUSIONS: Our findings represent the discovery of potential neoantigen expression driven by structural chromosomal rearrangements. These results may have implications for the development of novel immunotherapeutic strategies and the selection of patients to receive immunotherapies.
Copyright © 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chromoplexy; Chromosomal rearrangements; Chromothripsis; Mesothelioma; Neoantigens

Mesh:

Substances:

Year:  2018        PMID: 30316012      PMCID: PMC6348045          DOI: 10.1016/j.jtho.2018.10.001

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  51 in total

1.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system.

Authors:  Massimo Andreatta; Morten Nielsen
Journal:  Bioinformatics       Date:  2015-10-29       Impact factor: 6.937

Review 2.  'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.

Authors:  Eric Tran; Paul F Robbins; Steven A Rosenberg
Journal:  Nat Immunol       Date:  2017-02-15       Impact factor: 25.606

3.  Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations.

Authors:  Raphael Bueno; Eric W Stawiski; Leonard D Goldstein; Steffen Durinck; Assunta De Rienzo; Zora Modrusan; Florian Gnad; Thong T Nguyen; Bijay S Jaiswal; Lucian R Chirieac; Daniele Sciaranghella; Nhien Dao; Corinne E Gustafson; Kiara J Munir; Jason A Hackney; Amitabha Chaudhuri; Ravi Gupta; Joseph Guillory; Karen Toy; Connie Ha; Ying-Jiun Chen; Jeremy Stinson; Subhra Chaudhuri; Na Zhang; Thomas D Wu; David J Sugarbaker; Frederic J de Sauvage; William G Richards; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2016-02-29       Impact factor: 38.330

4.  Genome U-Plot: a whole genome visualization.

Authors:  Athanasios Gaitatzes; Sarah H Johnson; James B Smadbeck; George Vasmatzis
Journal:  Bioinformatics       Date:  2018-05-15       Impact factor: 6.937

5.  Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.

Authors:  Samra Turajlic; Kevin Litchfield; Hang Xu; Rachel Rosenthal; Nicholas McGranahan; James L Reading; Yien Ning S Wong; Andrew Rowan; Nnennaya Kanu; Maise Al Bakir; Tim Chambers; Roberto Salgado; Peter Savas; Sherene Loi; Nicolai J Birkbak; Laurent Sansregret; Martin Gore; James Larkin; Sergio A Quezada; Charles Swanton
Journal:  Lancet Oncol       Date:  2017-07-07       Impact factor: 41.316

6.  Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.

Authors:  Rebecca L Boddicker; Gina L Razidlo; Surendra Dasari; Yu Zeng; Guangzhen Hu; Ryan A Knudson; Patricia T Greipp; Jaime I Davila; Sarah H Johnson; Julie C Porcher; James B Smadbeck; Bruce W Eckloff; Daniel D Billadeau; Paul J Kurtin; Mark A McNiven; Brian K Link; Stephen M Ansell; James R Cerhan; Yan W Asmann; George Vasmatzis; Andrew L Feldman
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

7.  Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer.

Authors:  Aaron S Mansfield; Stephen J Murphy; Tobias Peikert; Eunhee S Yi; George Vasmatzis; Dennis A Wigle; Marie Christine Aubry
Journal:  Clin Cancer Res       Date:  2015-12-14       Impact factor: 12.531

8.  The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain.

Authors:  Lauren T Gehman; Peter Stoilov; Jamie Maguire; Andrey Damianov; Chia-Ho Lin; Lily Shiue; Manuel Ares; Istvan Mody; Douglas L Black
Journal:  Nat Genet       Date:  2011-05-29       Impact factor: 38.330

9.  Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen.

Authors:  Jenette Creaney; Shaokang Ma; Sophie A Sneddon; Michelle R Tourigny; Ian M Dick; Justine S Leon; Andrea Khong; Scott A Fisher; Richard A Lake; W Joost Lesterhuis; Anna K Nowak; Shay Leary; Mark W Watson; Bruce W Robinson
Journal:  Oncoimmunology       Date:  2015-05-11       Impact factor: 8.110

10.  Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.

Authors:  A S Mansfield; M C Aubry; J C Moser; S M Harrington; R S Dronca; S S Park; H Dong
Journal:  Ann Oncol       Date:  2016-08-08       Impact factor: 32.976

View more
  36 in total

Review 1.  Use of Immune Checkpoint Inhibitors in Mesothelioma.

Authors:  Patrick M Forde; Arnaud Scherpereel; Anne S Tsao
Journal:  Curr Treat Options Oncol       Date:  2019-02-14

Review 2.  Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas.

Authors:  Lynnette Fernandez-Cuesta; Lise Mangiante; Nicolas Alcala; Matthieu Foll
Journal:  Virchows Arch       Date:  2021-01-07       Impact factor: 4.064

Review 3.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

4.  Nivo-lution in Mesothelioma.

Authors:  Aaron S Mansfield; Marjorie G Zauderer
Journal:  Clin Cancer Res       Date:  2019-07-17       Impact factor: 12.531

5.  Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.

Authors:  Wanyuan Cui; Sanjay Popat
Journal:  Drugs       Date:  2021-06-09       Impact factor: 9.546

Review 6.  New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.

Authors:  Anne S Tsao; Harvey I Pass; Andreas Rimner; Aaron S Mansfield
Journal:  J Clin Oncol       Date:  2022-01-05       Impact factor: 44.544

7.  Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.

Authors:  Runzhe Chen; Won-Chul Lee; Anne S Tsao; Jianjun Zhang; Junya Fujimoto; Jun Li; Xin Hu; Reza Mehran; David Rice; Stephen G Swisher; Boris Sepesi; Hai T Tran; Chi-Wan Chow; Latasha D Little; Curtis Gumbs; Cara Haymaker; John V Heymach; Ignacio I Wistuba; J Jack Lee; P Andrew Futreal; Jianhua Zhang; Alexandre Reuben
Journal:  Clin Cancer Res       Date:  2020-08-14       Impact factor: 12.531

8.  Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?

Authors:  Michele Carbone; Haining Yang; Giovanni Gaudino
Journal:  J Thorac Oncol       Date:  2018-12-28       Impact factor: 15.609

9.  RUNX2 (6p21.1) amplification in osteosarcoma.

Authors:  Sounak Gupta; Tatsuo Ito; Deepu Alex; Chad M Vanderbilt; Jason C Chang; Nasrin Islamdoust; Yanming Zhang; Khedoudja Nafa; John Healey; Marc Ladanyi; Meera R Hameed
Journal:  Hum Pathol       Date:  2019-10-25       Impact factor: 3.466

10.  [Research Progress on Heterogeneity of Tumor Mutation Burden in Patients with 
Non-small Cell Lung Cancer].

Authors:  Abdurazik Mihray; Peng Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.